Table 4.

PASI90 and PASI100 response percentage rates during different timepoints and impact of several clinical characteristics of patients on therapeutic response to risankizumab in real-life studies published to date, together with our study. Only studies including ≥50 subjects with treatment duration longer than 28 weeks were included.

Referrence, No of Subjects	Efficacy (PASI90/PASI100)
Week of Therapy	Week 4	Week 16	Week 28	Week 40	Week 52	Week 96/104
Gkalpakiotis et al., n = 154 [16]	N/A	63.8/44.7	77.3/59.1	N/A	82.4/67.7	N/A
Gargiulo et al., n = 131 [10]	N/A	55.7/36.6	65.7/47.3	N/A	78.6/61.1	80.8/69.2
Graier et al., n = 55 [11]	N/A	63.9/42.6	70.0/50.0	N/A	72.0/60.0	N/A
Borroni et al., n = 66 [12]	N/A	61.0/28.6	N/A	85.5/62.3	N/A	N/A
Caldarola et al., n = 112 [15]	17.9/10.7	72.2/55.6	91.0/75.0	N/A	95.2/90.4	N/A
Mastorino et al., n = 166 [14]	N/A	53.0/32.0	72.0/51/0	73.0/53.0	82.0/73.0	N/A
Our study	13.2/2.9	81.4/53.1	87.0/67.0	86.0/68.8	88.7/71.0	81.8/68.2
Disease/subject characteristics	BMI	Age	Duration of disease	Previous biologic therapy	Psoriatic arthritis	Cardiometabolic comorbidities
Gkalpakiotis et al., n = 154	No impact	N/A	N/A	No impact	N/A	N/A
Gargiulo et al., n = 131	No impact	N/A	N/A	No impact	No impact	No impact
Borroni et al., n = 66	Lower response	N/A	N/A	Lower response	N/A	No impact
Caldarola et al., n = 112	No impact	Lower response	N/A	No impact	N/A	N/A
Mastorino et al., n = 166	Lower response	N/A	N/A	Lower response	Lower response	N/A
Our study	No impact	Lower response	Lower response	No impact	Lower response	Lower response

BMI—Body mass index, N/A—not assessed.